P0636 : Antiviral efficacy and induction of host immune responses with SB 9200, an oral prodrug of the dinucleotide SB 9000, in the woodchuck model of chronic hepatitis B virus (HBV) infection

Korolowicz, Kyle E.; Czerwinski, Stefanie; Iyer, Radhakrishnan P.; Skell, Jeffrey; Yang, Junming; Tucker, Robin D.; Menne, Stephan

doi:10.1016/s0168-8278(15)30841-2

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Agonists of TLR7, TLR8, RIG-I, and stimulator of interferon genes (STING) have been under various stages of clinical development for treatment of CHB as discussed below. (143). However, the clinical development of a RIG-I agonist, SB9200, was recently terminated because of drug-associated lethal affects in a clinical trial.…”

Section: Activation Of Innate Immunity By Pattern Recognition Receptor Agonistsmentioning

confidence: 99%

Prospects for the Global Elimination of Hepatitis B

2021

View full text Add to dashboard Cite

Chronic hepatitis B virus (HBV) infection is the leading cause of liver cirrhosis and hepatocellular carcinoma, estimated to be globally responsible for ∼800,000 deaths annually. Although effective vaccines are available to prevent new HBV infection, treatment of existing chronic hepatitis B (CHB) is limited, as the current standard-of-care antiviral drugs can only suppress viral replication without achieving cure. In 2016, the World Health Organization called for the elimination of viral hepatitis as a global public health threat by 2030. The United States and other nations are working to meet this ambitious goal by developing strategies to cure CHB, as well as prevent HBV transmission. This review considers recent research progress in understanding HBV pathobiology and development of therapeutics for the cure of CHB, which is necessary for elimination of hepatitis B by 2030.

show abstract

Section: Activation Of Innate Immunity By Pattern Recognition Receptor Agonistsmentioning

confidence: 99%

Prospects for the Global Elimination of Hepatitis B

2021

View full text Add to dashboard Cite

show abstract

“…It is thought to modulate host immune response to viral infection and activate host proteins RIG-1 and NOD2. Oral administration of SB9200 in woodchucks with chronic woodchuck hepatitis B (WHBV) infection reduced serum levels of WHBV DNA and surface antigen [22].…”

Section: Immunomodulatorsmentioning

confidence: 99%

Future therapy for hepatitis B virus infection

Minami

2015

Clin J Gastroenterol

View full text Add to dashboard Cite

We can now control hepatitis B virus infection by continuously administering nucleoside and nucleotide analogues such as entecavir and tenofovir. These drugs are generally safe and sufficiently effective, but future drugs are needed that can show off-treatment efficacy--in other words, eradication of latent hepatitis B virus DNA (covalently closed circular DNA) in the hepatocytes. This article is an overview of new drugs under development and some novel strategies to inhibit hepatitis B virus proliferation.

show abstract